Von Willebrand disease Ziekte van Von Willebrand Hemophilia A Hemofilie A Bloederziekte
Conditions
Interventions
Two DDAVP infusions will be performed. The first DDAVP test will take place prior to starting statin therapy and the second test will be performed after 6 weeks of statin therapy. During both tests bl
Sponsors
Academic Medical Center, Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: 1. Mild hemophilia A, or; 2. Type 1 von Willebrand disease; 3. DDAVP response has been tested at least once before; 4. Age: 18 – 60 years; 5. Male; 6. Written informed consent is given.
Exclusion criteria
Exclusion criteria: 1. Moderate/Severe hemophilia A; 2. Type 2 or 3 von Willebrand diseas; 3. Clinical history of any other hemostatic or thrombotic disorder; 4. Allergy or contra-indication for Simvastatine or Minrin therapy; 5. Medical indication for statin therapy; 6. Co-enrolment in other clinical study in the last 3 months; 7. No previous DDAVP-test; 8. First relative (brother/sister) participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Von Willebrand factor antigen, von Willebrand factor activity and von Willebrand Factor propeptide plasma levels after DDAVP stimulation, during statin therapy; 2. Factor VIII activity and factor VIII antigen plasma levels after DDAVP stimulation, during statin therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Von Willebrand factor multimers, ADAMTS13 and tPA plasmalevels after DDAVP stimulation during statin therapy. | — |
Contacts
Public ContactC.L. Eckhardt
Meibergdreeg 9
Outcome results
None listed